Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study.

Sato T, Ambale-Venkatesh B, Lima JAC, Zimmerman SL, Tedford RJ, Fujii T, Hulme OL, Pullins EH, Corona-Villalobos CP, Zamanian RT, Minai OA, Girgis RE, Chin K, Khair R, Damico RL, Kolb TM, Mathai SC, Hassoun PM.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217748307. doi: 10.1177/2045893217748307. Epub 2017 Dec 18.

2.

Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Mercurio V, Mukherjee M, Tedford RJ, Zamanian RT, Khair RM, Sato T, Minai OA, Torres F, Girgis RE, Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):388-391. doi: 10.1164/rccm.201704-0789LE. No abstract available.

3.

Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study.

Gadre A, Ghattas C, Han X, Wang X, Minai O, Highland KB.

Lung. 2017 Oct;195(5):529-536. doi: 10.1007/s00408-017-0034-1. Epub 2017 Jun 23.

PMID:
28646245
4.

Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.

Ascha M, Zhou X, Rao Y, Minai OA, Tonelli AR.

Cardiovasc Ther. 2017 Oct;35(5). doi: 10.1111/1755-5922.12281.

5.

Lung or Heart-Lung Transplant in Pulmonary Arterial Hypertension: What Is the Impact of Systemic Sclerosis?

Gadre SK, Minai OA, Wang XF, Zhang Q, Budev M, Tonelli AR.

Exp Clin Transplant. 2017 Dec;15(6):676-684. doi: 10.6002/ect.2016.0209. Epub 2017 May 22.

6.

Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment.

Mathai SC, Minai O, Sullivan SD, Lerner D, Levine D.

Respir Med. 2017 Jan;122 Suppl 1:S23-S27. doi: 10.1016/j.rmed.2016.11.002. Epub 2016 Nov 2.

7.

Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.

Rose JA, Cleveland JM, Rao Y, Minai OA, Tonelli AR.

Chest. 2016 May;149(5):1234-44. doi: 10.1016/j.chest.2015.11.008. Epub 2016 Jan 13.

8.

Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.

Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA.

Pulm Circ. 2015 Sep;5(3):565-76. doi: 10.1086/682432.

9.

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10. doi: 10.1164/rccm.201507-1398OC.

10.

Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis.

Bandyopadhyay D, Bajaj NS, Zein J, Minai OA, Dweik RA.

Eur Respir J. 2015 Sep;46(3):750-60. doi: 10.1183/09031936.00215514. Epub 2015 May 28.

11.

Association of impaired heart rate recovery with cardiopulmonary complications after lung cancer resection surgery.

Ha D, Choi H, Zell K, Raymond DP, Stephans K, Wang XF, Videtic G, McCarthy K, Minai OA, Mazzone PJ.

J Thorac Cardiovasc Surg. 2015 Apr;149(4):1168-73.e3. doi: 10.1016/j.jtcvs.2014.11.037. Epub 2014 Nov 21.

12.

Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer.

Ha D, Stephans K, Choi H, Zell K, Wang XF, Minai OA, Raymond DP, Videtic G, Mazzone PJ.

J Radiosurg SBRT. 2015;3(3):193-201.

13.
14.
15.

Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates.

Idrees MM, Saleemi S, Azem MA, Aldammas S, Alhazmi M, Khan J, Gari A, Aldabbagh M, Sakkijha H, Aldalaan A, Alnajashi K, Alhabeeb W, Nizami I, Kouatli A, Chehab M, Tamimi O, Banjar H, Kashour T, Lopes A, Minai O, Hassoun P, Pasha Q, Mayer E, Butrous G, Bhagavathula S, Ghio S, Swiston J, Boueiz A, Tonelli A, Levy RD, Hoeper M, Levy RD.

Ann Thorac Med. 2014 Jul;9(Suppl 1):S1-S15. doi: 10.4103/1817-1737.134006.

16.

Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure.

Heresi GA, Minai OA, Tonelli AR, Hammel JP, Farha S, Parambil JG, Dweik RA.

Pulm Circ. 2013 Dec;3(4):916-25. doi: 10.1086/674756.

17.

Impaired functional capacity predicts mortality in patients with obstructive sleep apnea.

Nisar SA, Muppidi R, Duggal S, Hernandez AV, Kalahasti V, Jaber W, Minai OA.

Ann Am Thorac Soc. 2014 Sep;11(7):1056-63. doi: 10.1513/AnnalsATS.201309-315OC.

PMID:
24983954
18.

Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls.

Tonelli AR, Wang XF, Alkukhun L, Zhang Q, Dweik RA, Minai OA.

Physiol Rep. 2014 Jun 11;2(6). pii: e12038. doi: 10.14814/phy2.12038. Print 2014 Jun 1.

19.

Presence and outcomes of kidney disease in patients with pulmonary hypertension.

Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, Nally JV Jr, Schold JD, Rahman M, Dweik RA.

Clin J Am Soc Nephrol. 2014 May;9(5):855-63. doi: 10.2215/CJN.10191013. Epub 2014 Feb 27.

20.

Electrocardiography at diagnosis and close to the time of death in pulmonary arterial hypertension.

Tonelli AR, Baumgartner M, Alkukhun L, Minai OA, Dweik RA.

Ann Noninvasive Electrocardiol. 2014 May;19(3):258-65. doi: 10.1111/anec.12125. Epub 2013 Dec 30.

21.

Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.

Tonelli AR, Alkukhun L, Arelli V, Ramos J, Newman J, McCarthy K, Pichurko B, Minai OA, Dweik RA.

Clin Transl Sci. 2013 Dec;6(6):474-80. doi: 10.1111/cts.12090. Epub 2013 Sep 6.

22.

Clinical characteristics and prediction of pulmonary hypertension in severe emphysema.

Minai OA, Fessler H, Stoller JK, Criner GJ, Scharf SM, Meli Y, Nutter B, DeCamp MM; NETT Research Group.

Respir Med. 2014 Mar;108(3):482-90. doi: 10.1016/j.rmed.2013.11.006. Epub 2013 Nov 19.

23.

Perioperative risk and management in patients with pulmonary hypertension.

Minai OA, Yared JP, Kaw R, Subramaniam K, Hill NS.

Chest. 2013 Jul;144(1):329-340. doi: 10.1378/chest.12-1752. Review.

PMID:
23880683
24.

Long-term continuous positive airway pressure therapy normalizes high exhaled nitric oxide levels in obstructive sleep apnea.

Chua AP, Aboussouan LS, Minai OA, Paschke K, Laskowski D, Dweik RA.

J Clin Sleep Med. 2013 Jun 15;9(6):529-35. doi: 10.5664/jcsm.2740.

25.

Updating clinical endpoint definitions.

Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, Meier C, Ghofrani AH, Minai O, Rinaldi P, Michelakis E, Oudiz RJ.

Pulm Circ. 2013 Jan;3(1):206-16. doi: 10.4103/2045-8932.109920.

26.

Causes and circumstances of death in pulmonary arterial hypertension.

Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA, Dweik RA.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):365-9. doi: 10.1164/rccm.201209-1640OC.

27.

Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.

Minai OA, Parambil J, Dweik RA, Davila GH, Peterson L, Rollins KD, Chen H.

Respir Med. 2013 Mar;107(3):458-65. doi: 10.1016/j.rmed.2012.10.023. Epub 2012 Dec 21.

28.

Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis.

Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K.

Respir Med. 2012 Nov;106(11):1613-21. doi: 10.1016/j.rmed.2012.07.013. Epub 2012 Aug 16.

29.

Prevalence and significance of decreased bone density in pulmonary arterial hypertension.

Malik N, McCarthy K, Minai OA.

South Med J. 2012 Jul;105(7):344-9. doi: 10.1097/SMJ.0b013e31825b8117.

PMID:
22766660
30.

Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension.

Batal O, Faulx M, Krasuski RA, Khatib OF, Hammel JP, Hussein AA, Minai OA, Dweik RA.

Am J Cardiol. 2012 Sep 15;110(6):909-14. doi: 10.1016/j.amjcard.2012.05.017. Epub 2012 Jun 8.

PMID:
22683040
31.

Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving ≤2 years and those surviving ≥5 years after baseline right-sided cardiac catheterization.

Batal O, Khatib OF, Dweik RA, Hammel JP, McCarthy K, Minai OA.

Am J Cardiol. 2012 May 15;109(10):1514-20. doi: 10.1016/j.amjcard.2012.01.366. Epub 2012 Feb 22.

PMID:
22360818
32.

Pulmonary hypertension before first and second lung transplantation.

Tonelli AR, Timofte I, Minai OA, Baz M, Akindipe O.

Clin Transplant. 2012 Sep-Oct;26(5):672-8. doi: 10.1111/j.1399-0012.2011.01588.x. Epub 2012 Feb 10.

33.

Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide.

Aytekin M, Aulak KS, Haserodt S, Chakravarti R, Cody J, Minai OA, Dweik RA.

Am J Physiol Lung Cell Mol Physiol. 2012 Mar 15;302(6):L512-20. doi: 10.1152/ajplung.00289.2011. Epub 2012 Jan 13.

34.

Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension.

Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA.

Am J Respir Crit Care Med. 2012 Feb 15;185(4):400-8. doi: 10.1164/rccm.201105-0848OC. Epub 2011 Nov 22.

PMID:
22108205
35.

Lung deflation and oxygen pulse in COPD: results from the NETT randomized trial.

Come CE, Divo MJ, San José Estépar R, Sciurba FC, Criner GJ, Marchetti N, Scharf SM, Mosenifar Z, Make BJ, Keller CA, Minai OA, Martinez FJ, Han MK, Reilly JJ, Celli BR, Washko GR; NETT Research Group.

Respir Med. 2012 Jan;106(1):109-19. doi: 10.1016/j.rmed.2011.07.012. Epub 2011 Aug 16.

36.

A 60-year old man presenting with yellow nail syndrome.

Modrykamien A, Minai O.

Respir Care. 2011 Jul;56(7):1043-5. doi: 10.4187/respcare.00942. Epub 2011 Feb 21. No abstract available.

37.

Pulmonary hypertension: an important predictor of outcomes in patients undergoing non-cardiac surgery.

Kaw R, Pasupuleti V, Deshpande A, Hamieh T, Walker E, Minai OA.

Respir Med. 2011 Apr;105(4):619-24. doi: 10.1016/j.rmed.2010.12.006. Epub 2010 Dec 31.

38.

Sleep quality, depression, and quality of life in patients with pulmonary hypertension.

Batal O, Khatib OF, Bair N, Aboussouan LS, Minai OA.

Lung. 2011 Apr;189(2):141-9. doi: 10.1007/s00408-010-9277-9. Epub 2010 Dec 21.

PMID:
21174111
39.

Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective.

Minai OA, Chaouat A, Adnot S.

Chest. 2010 Jun;137(6 Suppl):39S-51S. doi: 10.1378/chest.10-0087.

PMID:
20522579
40.

Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns.

Minai OA, Nathan SD, Hill NS, Badesch DB, Stoller JK.

Respir Med. 2010 May;104(5):741-8. doi: 10.1016/j.rmed.2009.12.015. Epub 2010 Jan 21.

41.

Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome.

Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K, Golish JA, Stoller JK.

Am J Cardiol. 2009 Nov 1;104(9):1300-6. doi: 10.1016/j.amjcard.2009.06.048.

PMID:
19840581
42.
43.

Safety of diagnostic bronchoscopy in patients with pulmonary hypertension.

Diaz-Guzman E, Vadi S, Minai OA, Gildea TR, Mehta AC.

Respiration. 2009;77(3):292-7. doi: 10.1159/000197465. Epub 2009 Jan 28.

PMID:
19174601
44.

An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?

Minai O.

Lupus. 2009 Jan;18(1):92. doi: 10.1177/0961203308098361. No abstract available.

PMID:
19074176
45.

Bronchogenic carcinoma after lung transplantation: characteristics and outcomes.

Minai OA, Shah S, Mazzone P, Budev MM, Sahoo D, Murthy S, Mason D, Pettersson G, Mehta AC.

J Thorac Oncol. 2008 Dec;3(12):1404-9. doi: 10.1097/JTO.0b013e31818e1259.

46.

Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients.

Poonyagariyagorn HK, Gershman A, Avery R, Minai O, Blazey H, Asamoto K, Alster J, Murthy S, Mehta A, Pettersson G, Mason DP, Budev M.

Transpl Infect Dis. 2008 Dec;10(6):403-8. doi: 10.1111/j.1399-3062.2008.00338.x. Epub 2008 Sep 15.

PMID:
18823356
47.

BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.

Rigelsky CM, Jennings C, Lehtonen R, Minai OA, Eng C, Aldred MA.

Am J Med Genet A. 2008 Oct 1;146A(19):2551-6. doi: 10.1002/ajmg.a.32468.

PMID:
18792970
48.

Inflammatory myofibroblastic tumor of the lung: recurrence after steroid treatment.

Schaeffer CJ, Minai OA, Sharma N, Kanne JP, Mohammed TL.

J Thorac Imaging. 2008 Aug;23(3):191-3. doi: 10.1097/RTI.0b013e31816591a4.

PMID:
18728547
49.

Bosentan in systemic sclerosis.

Heresi GA, Minai OA.

Drugs Today (Barc). 2008 Jun;44(6):415-28. doi: 10.1358/dot.2008.44.6.1220138. Review.

PMID:
18596996
50.

Comorbidities in chronic obstructive pulmonary disease.

Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ.

Proc Am Thorac Soc. 2008 May 1;5(4):549-55. doi: 10.1513/pats.200709-148ET. Review.

Supplemental Content

Support Center